7 results match your criteria: "Hospital Ruber Juan Bravo and Universidad Europea[Affiliation]"
Dermatologic immune-related adverse events: It is time for a game change!
J Eur Acad Dermatol Venereol
August 2024
Oncodermatology Clinic, Hospital Ruber Juan Bravo and Universidad Europea, Madrid, Spain.
Supportive oncodermatology practices in Europe and the USA.
J Eur Acad Dermatol Venereol
May 2024
Oncodermatology Department, Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
Cyclin-Dependent Kinase 4/6 Inhibitors and Dermatologic Adverse Events: Results from the EADV Task Force "Dermatology for Cancer Patients" International Study.
Cancers (Basel)
July 2023
UOC Dermatologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Article Synopsis
- The study investigates cutaneous adverse reactions in advanced breast cancer patients treated with cyclin-dependent kinase inhibitors (CDK4/6i), focusing on their types, severity, and treatment outcomes.
- Researchers analyzed data from 79 patients across 11 countries, documenting 165 skin-related issues, with the most common being pruritus, alopecia, and eczematous lesions.
- Most reactions were mild and managed with topical treatments, with only a small percentage leading to treatment discontinuation.
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases.
Melanoma Res
April 2023
EADV European Task Force 'Dermatology for cancer patients'.
Article Synopsis
- Immune checkpoint inhibitors (ICIs) can rarely cause a serious skin reaction known as drug reactions with eosinophilia and systemic symptoms (DRESS), and this study aims to outline its clinical features, treatment, and prognosis.
- The study analyzed 13 patients who reported DRESS after ICI treatment, noting symptoms like fever, skin rash, and facial swelling, with a median onset of 22 days after starting the medication.
- Treatment typically involved stopping the ICI and administering systemic steroids, with most patients experiencing moderate severity and no fatalities linked to DRESS; however, a consensus on the best management practices is still needed.
Clinical characterization and treatment outcomes of follicular cutaneous immune-related adverse events caused by immune checkpoint inhibitors: A multicenter retrospective study.
J Am Acad Dermatol
March 2023
Oncodermatology Department, Institut Universitaire du cancer, Toulouse Oncopole, Toulouse, France.
Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Br J Dermatol
December 2022
Institut Universitaire du Cancer, Toulouse Oncopole, Toulouse, France.
Article Synopsis
- Cutaneous immune-related adverse events (irAEs) are the most common side effects experienced by cancer patients undergoing treatment with immune checkpoint inhibitors (ICIs), with a wide variety of skin toxicities identified.
- A study of 762 patients revealed 993 instances of cutaneous toxicities, with psoriasis and pruritus being the most prevalent reactions.
- The findings indicate that the type of ICI therapy and the underlying cancer can significantly influence the occurrence and type of skin toxicities, highlighting the need for tailored follow-up plans for affected patients.
Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer.
JAMA Dermatol
September 2020
Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Importance: Persistent radiation-induced alopecia (pRIA) and its management have not been systematically described.
Objective: To characterize pRIA in patients with primary central nervous system (CNS) tumors or head and neck sarcoma.
Design, Setting, And Participants: A retrospective cohort study of patients from January 1, 2011, to January 30, 2019, was conducted at 2 large tertiary care hospitals and comprehensive cancer centers.